Multimeric Biotherapeutics Email Format

BiotechnologyUnited States2-10 Employees

Multimeric Biotherapeutics, Inc. is a United States–based biotechnology company focused on developing and applying proteins from the TNF SuperFamily to create highly active multi-trimer soluble ligands. Its leading program, MegaCD40L, comprises a two-trimer form of CD40L designed to stimulate immune responses, with potential uses as both a vaccine adjuvant and an immune activator against tumors in preclinical studies. The company also pursues follow-on products that enhance signaling through related receptors, aiming to expand its immunotherapy portfolio. Initial clinical targets include ovarian cancer, with additional exploration of MegaCD40L as a vaccine adjuvant supported by NIH grants, and broader applications in vaccine development. In recent activity, the company participated in the Keystone Symposium on Innovative Vaccine Approaches, signaling ongoing engagement with the broader vaccine and immunotherapy community.

Get verified Multimeric Biotherapeutics emails free

Company overview Employee directory